Dolutegravir-based second-line ART achieves excellent virological outcomes even in the presence of resistance to recycled NRTIs
Atripla or efavirenz plus Truvada failed one in 16 people in first year
South Africa reports successful third-line HIV treatment programme
Dolutegravir plus darunavir maintains viral suppression without NRTIs
Two-drug protease inhibitor treatment as effective as three-drug treatment – and fewer stop due to side-effects
Drug resistance accumulates fast in people with low but detectable viral loads, Kenyan study finds
Studies confirm long-term effectiveness of new single-tablet regimens
Doravirine combination works well as a switch option
Studies show dolutegravir monotherapy is an unsafe switch option
